IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphoma.

Van Der Weyden, Carrie; Bagot, Martine; Neeson, Paul; Darcy, Phil K; Prince, H Miles

Van Der Weyden, Carrie; Bagot, Martine; Neeson, Paul; Darcy, Phil K; Prince, H Miles.

Affiliation

Van Der Weyden C; a Department of Haematology , Peter MacCallum Cancer Centre , Melbourne , Victoria , Australia.
Bagot M; b Department of Dermatology , Hôpital Saint-Louis , Paris , France.
Neeson P; c Inserm U976 , Paris , France.
Darcy PK; d Cancer Immunology Program , Peter MacCallum Cancer Centre , Melbourne , Victoria , Australia.
Prince HM; d Cancer Immunology Program , Peter MacCallum Cancer Centre , Melbourne , Victoria , Australia.

Expert Opin Investig Drugs ; 27(8): 691-697, 2018 Aug.

Article in En | MEDLINE | ID: mdl-30001170

Subject(s)

Lymphoma, T-Cell, Cutaneous/drug therapy; Receptors, KIR3DL2/immunology; Animals; Antibodies, Monoclonal/adverse effects; Antibodies, Monoclonal/pharmacology; Antibodies, Monoclonal/therapeutic use; Antineoplastic Agents/adverse effects; Antineoplastic Agents/pharmacology; Antineoplastic Agents/therapeutic use; Humans; Lymphoma, T-Cell, Cutaneous/immunology

Key words

Cutaneous T-cell lymphoma; IPH4102; KIR3DL2; Sézary syndrome; monoclonal antibody; mycosis fungoides

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lymphoma, T-Cell, Cutaneous / Receptors, KIR3DL2 Limits: Animals / Humans Language: En Journal: Expert Opin Investig Drugs Journal subject: TERAPIA POR MEDICAMENTOS Year: 2018 Document type: Article Affiliation country: Australia Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google